Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ACTINIUM PHARMACEUTICALS, INC. reported revenue of $0M. Operating margin was -40274.4% and net margin -37652.2%, on a free-cash-flow margin of -27426.7% with capital expenditure at 115.6% of revenue. Every figure is computed directly from ATNM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -40274.4% | -37652.2% |
| FY2024 | n/a | n/a | n/a |
| FY2023 | $0M | -64098.8% | -60269.1% |
| FY2022 | $1M | -3311.1% | -3205.5% |
| FY2021 | $1M | -2182.2% | -2165.6% |
How does ATNM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.